Analysts have turned bearish on CanSino Biologics, slashing ...
Analysts have turned bearish on CanSino Biologics, slashing next year's revenue estimates and predicting losses. Despite downgrades, they still foresee CanSino outpacing the broader industry.
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more